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“We will restore science to its rightful place, and wield technology’s wonders
to raise health care’s quality and lower its cost.”
President Barack Obama’s Inaugural Address
January 20th, 2009
The joy of the recent inauguration of Barack Obama as
President of The United States has given a bounce to
medicine and scientific communities, with the no-growth
science policies of the past administration ushered out,
replaced by promises of enhanced support for science and
health care reform [1]. The past eight years of the Bush
administration have seen National Institutes of Health (NIH)
funding increase by about 20% for the first four years,
followed by decreases over the later four years [2]. The recent
stagflation of science spending has resulted in significant
hardship for biomedical research.
Whereas NIH research funding has remained flat of late,
the upward trend of health care spending continues. It is now
estimated that US health care spending is more than 17% of
the Gross Domestic Product (GDP), the highest percentage
in the world [3]. This spending occurs at a time when 46
million Americans, or 15% of the population, do not have
health insurance [3]. Recognizing major problems of the
current health care system, federal spending on health care
will increase by the hundreds of billions of dollars. However,
investment in research and health care will be tempered by
the horrible national budget deficit and the poor economy.
Thus, health care will “need to do more with less.”
The consequences of the United States and global
financial crises are real and impact all of us in medicine,
either these eﬀects be direct or indirect. Direct consequences
of the crisis are funded projects stopped midstream, when
the coﬀers of foundations supporting research had their
valuations of 40% or more, or were swindled [4]. Direct
consequences of reduced federal support of research are
marked drops in pay lines by NIH institutes to single digits.
Direct consequences of the current situation are falling
revenues of pharmaceutical companies, leading to reduced
industry-sponsored research. Direct consequences come
from reduced philanthropic support of medical research and
social programs by universal belt-tightening.
Indirect consequences of the current fiscal meltdown
come from the parents of our patients in our care who
have lost their jobs and no longer have health insurance,
leading to reduced hospital revenues. Indirect consequences
come when spouses of medical workers loose their jobs
and the families relocate taking away valuable medical team
members. Indirect consequences related to new hardships
of recruiting, which already very diﬃcult in academic
pediatrics, are challenged by the inability to sell one’s home
or to obtain mortgage financing in the new community.
Academic medicine has gone through a painful period
over the past decade. Talks of “where were all the young
ones gone,” lamenting the dwindling pipeline of young
research talent, dominated the early part of the current
decade. Such commentaries have now expanded to lament
the fall of academic departments and entire disciplines [5, 6].
In pediatrics, research funding has dropped by substantial
amounts over the past decade [5–7].
Much of the leadership in pediatrics and pediatric
endocrinology, by virtue of being born in the 40 s, 50 s,
or 60 s, knows the landscape of the past years of healthy
funding and reimbursement rates; but, the academic and
2 International Journal of Pediatric Endocrinology
clinical care plains are diﬀerent now, and will continue to
evolve, aﬀected by market and federal events with permanent
impact. Whether we like it or not, new times are here.
The core commitment to basic academic principles—the
significant scientific advancement of our field, the training of
the next generation of clinicians and scholars, and ensuring
the health of the boys and girls in our care—will remain as
basic tenets. What we need to consider is how will we meet
these obligations with less resources. How and where should
the old-world of academic endocrinology changed?
One can legitimately ask, for example, can we still
aﬀord to fund fellows for three years, as mandated by the
American Board of Pediatrics, when fellows desire clinician
or clinician educator positions. There are about 50 first-
year fellows in Pediatric Endocrinology in the United States.
A third year of fellowship for three quarters of this group
costs collective $2.5 million annually, and contributes to our
current subspecailist shortage.
We need to revisit the current expensive model of
physician-only care. As with many centers where diabetes
care is delivered largely by nurses or nurse practitioners,
such models will need to be expanded for general pediatric
endocrinology care.
We need to evaluate the cost-eﬀectiveness of basic
practice approaches. Is there benefit to see a child on growth
hormone therapy three or four months, as many in the
field do, versus every six months? Why do we commit
some patients to long-term antithyroid drug therapy for
Graves’ disease, along with associated risks and extra costs,
when we can predict at the onset that chances of remission
oﬀ antithyroid medicine are slim? Why do we universally
perform expensive stimulation testing for growth hormone
deficiency at the behest of insurance companies, when we
have little faith in such studies?
We need to revisit the corporate influences that drive the
cost of our practice. The Veterans Hospitals Administration
and several health maintenance organizations, control costs
by limiting the drugs that can be prescribed, shunning higher
price new drugs in favor of generic compounds with proven
eﬃcacy and safety. We need to ask ourselves what are the
true advantages of the classic growth hormone products over
the lower-priced biosimilar growth hormone. We need to ask
ourselves, what are the true advantages of new and more
expensive preparations of drugs used to stop puberty over
products that are available for more than a decade. Why do
we not prescribe generic levo-thyroxine for all hypothyroid
patients on such therapy?
We need to ask ourselves do we all need to oﬀer specialty
endocrine surgery programs such as for hyperinsulinism
or thyroid disorders, when data clearly show that children
are best cared for at high volume and specialty centers of
excellence. Some insurance companies will give patients a
bonus if they go to specialty centers, with the hope that
minimizing complication risks will save dollar in the future.
Washington is now abuzz with talk of health care reform,
which will take a long and laborious trail. It is clear that
new economic models for health care delivery are needed to
provide health care to all and to avail us the rich benefit of
improving clinical care through biomedical research.
The time for head-wagging and fist-pumping in lament
of the past ways of the academic center and biomedical
research has past. It is clear that we are all going to have to do
more with less. Commensurate the new hope of action that
has arrived in Washington, it is now our turn to work for a
“new deal” that will reshape our profession into a realistic
model for the lasting and chilly times ahead for academic
medicine and health care.
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